Global Cannabis $APP In Deal With Artificial Intelligence Provider

Global Cannabis App(CSE:APP, FWB:2FA, OTCQB:FUAPF)

Global Cannabis Applications Corp., a leading developer of innovative data technologies for the cannabis industry,  is pleased to announce that Global Cannabis Apps Corporation Pty. Ltd., the Company’s 61% subsidiary in Australia, has secured an exclusive global license for Medical Cannabis Artificial Intelligence regulation technology with  Australian-based Compliance Master International.

GCAC Australia will hold the exclusive global usage and distribution rights to ‘Cannabis Compliance AI’ – a cutting edge AI risk-based auditing and inspection technology to be rolled out to the global medical cannabis industry.

One of the biggest challenges facing governments is establishing the necessary regulatory structures and processes needed to reliably monitor and control quality and supply-chain risks of medical cannabis, while reducing the costs and burden placed on cannabis product producers and the public at the same time.

“Our Cannabis Compliance AI is going to be transformative technology for the industry as it grows.  Not only will it will help all participants from licensed producers to product producers monitor their regulatory requirements, it will save significant time and costs in regulation management, accelerate knowledge and facilitate unprecedented data sharing for the betterment of medical cannabis users.”

-Jason Webb, Chief Executive Officer of GCAC Australia

“This technology will help cement GCAC as the go-to medical cannabis data company.  At the front end, the AI will be extremely important in ensuring we collect the best data possible on products listed on our Prescriptii and CannaLife Apps.  At the back end, the AI compliance technology will further help us establish our credentials as the most trusted source of data from regulator to retail.”

-Brad Moore, Chief Executive Officer of GCAC

The ‘Cannabis Compliance AI’ will be a core component of the GCAC Blockchain and ICO. It is anticipated that the AI application will be very attractive to all spectrums of the medical cannabis industry and provide first revenue streams for GCAC Australia.